Amgen Files ITC Complaint Over Roche Anemia Drug

Law360, New York (April 12, 2006, 12:00 AM EDT) -- In a move to block pharmaceutical company Roche Holding AG’s experimental anemia drug from entering the United States, biotechnology company Amgen Inc. filed a complaint Tuesday with the U.S. International Trade Commission.

Amgen, the world’s largest biotechnology company, requested an investigation into the importation of the Swiss drug maker’s anemia drug Cera, or pegylated recombinant human erythropoietin (EPO), into the United States.

Amgen claimed Roche’s manufacturing procedure infringed six patents relating to Amgen’s Epogen, which is sold in the United States to treat anemia in patients...
To view the full article, register now.